Seniors’ Access to Critical Medications Act of 2025

1) What happened: On April 29, 2025, the House Energy and Commerce Committee ordered HR 2484 reported by a 38-7 vote. The bill creates a time-limited Stark law exception from 2026-2030 allowing physicians to dispense Part D covered outpatient drugs from their office, including via caregiver pickup and mail, so long as the prescribing physician has an ongoing relationship with the beneficiary and a qualifying in-person encounter occurred within the prior year. The bill has been reported out of committee and awaits floor action in the House. 2) The money trail: This bill authorizes no direct federal spending — it is a regulatory exemption bill. It removes a barrier to physicians' dispensing revenue, effectively allowing them to capture the spread between drug acquisition cost and reimbursement. No funds are appropriated. The economic transfer is from traditional pharmacy and PBM margins to physician practices. The CRS summary clarifies the bill only lifts the self-referral prohibition; no new payment mechanisms are created. 3) Structural winners and losers: The direct losers are retail pharmacy chains and PBMs. CVS, operating both retail pharmacies and the Caremark PBM, faces the largest single-company exposure as every diverted Part D prescription eliminates both retail margin and PBM processing fee. Cigna's Express Scripts is similarly exposed on the PBM side. UnitedHealth's Optum Rx loses PBM fees but UnitedHealth's Optum Health physician network can capture the dispensing margin, creating a partial natural hedge. Independent pharmacies and physician practice management companies (not publicly traded pure plays here) are structural beneficiaries. 4) Real market data analysis: As of April 30, 2026, CVS trades at $83.33, up 6.92% in 7 days and 16.03% in 30 days, approaching its 52-week high of $85.15. The stock has rallied from $77.30 on April 17. CI trades at $285.02, up 3.4% in 7 days and 6.85% in 30 days, with significant intraday volatility (closing $292.32 on April 29 before settling at $285.02 on April 30). UNH trades at $366.71, up 3.32% in 7 days and an outsized 35.52% in 30 days. The 30-day surge across healthcare names reflects broader sector rotation; CVS's acceleration from $76.43 (April 22) to $83.33 (April 30) appears partially correlated with the April 29 committee vote. 5) Timeline: The bill must pass the full House, then the Senate, then be signed by the President. It has 24 cosponsors including bipartisan support (Wasserman Schultz, D-FL is a cosponsor) but has not yet received a floor vote. The effective date is January 1, 2026 — if the bill does not complete passage by year-end, the January 1 start date is likely delayed. Current legislative calendar shows limited floor time before the August recess; likely path is post-Labor Day House passage with Senate action in Q4 2025.